There's no guarantee these stocks will double by 2030, but their growth prospects look great.
These rising drugmakers have serious arguments in their favor.
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to combat obesity. Is TERN stock a good buy right now?
Shares of the clinical-stage biotech have skyrocketed on recent good news.
Viking Therapeutics stock is on fire following a successful phase 2 trial for its obesity care candidate.
These businesses should see good times ahead.
The drugmaker isn't losing momentum.
Its long-term growth potential looks like it's improving, again.
These two healthcare stocks should have plenty of room to run.